Chemomab Therapeutics (NASDAQ:CMMB) Price Target Raised to $7.00

Chemomab Therapeutics (NASDAQ:CMMB) had its price target hoisted by equities research analysts at Maxim Group from $4.00 to $7.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Maxim Group’s target price points to a potential upside of 309.36% from the stock’s current price.

Separately, Oppenheimer reiterated an “outperform” rating and issued a $11.00 price objective (down previously from $13.00) on shares of Chemomab Therapeutics in a research note on Friday, November 15th.

Chemomab Therapeutics Stock Down 3.4 %

Shares of NASDAQ CMMB opened at $1.71 on Thursday. Chemomab Therapeutics has a 52 week low of $0.58 and a 52 week high of $2.55. The firm has a market cap of $24.55 million, a P/E ratio of -1.71 and a beta of 0.66. The business’s 50 day moving average price is $1.97 and its 200 day moving average price is $1.71.

Institutional Trading of Chemomab Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Sphera Funds Management LTD. acquired a new position in Chemomab Therapeutics in the third quarter valued at approximately $1,907,000. XTX Topco Ltd increased its holdings in shares of Chemomab Therapeutics by 63.8% during the 4th quarter. XTX Topco Ltd now owns 24,929 shares of the company’s stock valued at $45,000 after purchasing an additional 9,706 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of Chemomab Therapeutics in the 4th quarter valued at $26,000. Hedge funds and other institutional investors own 46.05% of the company’s stock.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).